Clinical laboratory
Legislation relating to FDA oversight of laboratory-developed test;
 
Federal policy related to implementation of Section 307 of H.R. 8406, the Heroes Act, provisions relating to coverage of COVID-19 testing;
 
Federal policy relating to drug development, including potential legislation known as Cures 2.0;
 
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; and
 
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93.
HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
KELLEY DRYE & WARREN LLP
3050 K STREET, NW, SUITE 400, WASHINGTON, DC, 20007, US
DANA SCHNEEBERGER WOOD SCOTT MCGEE